Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol.
about
The management of glaucoma and intraocular hypertension: current approaches and recent advancesMeta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertensionThe effect on intraocular pressure of latanoprost once or four times dailyGlaucoma medical treatment: philosophy, principles and practice.Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: a patient-use studyRecent advances in pharmacotherapy of glaucomaLong-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional study.Prostaglandin analogs in the treatment of glaucoma.Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension.Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertensionTherapeutic potential of prostaglandin analogues in glaucoma.Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management.The impact of intraocular pressure reduction on retinal ganglion cell function measured using pattern electroretinogram in eyes receiving latanoprost 0.005% versus placebo.A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension.Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish LaEmerging drugs for ophthalmic diseases.Additive effect of unoprostone and latanoprost in patients with elevated intraocular pressure.An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension.Patterns of opioid analgesic prescription among patients with osteoarthritis.24-hour intraocular pressure in glaucoma patients randomized to receive dorzolamide or brinzolamide in combination with latanoprost.A review of the use of latanoprost for glaucoma since its launch.Efficacy and safety of combination therapy with latanoprost after a change in therapeutic regimen from timolol to brinzolamide in Japanese adult patients with primary open-angle glaucoma and ocular hypertension: open, non-randomized 12-week study.Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension.Efficacy and safety of fixed combinations of latanoprost/timolol and dorzolamide/timolol in open-angle glaucoma or ocular hypertension.The effect on diurnal intraocular pressure of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension.Additive IOP-reducing effect of latanoprost in patients insufficiently controlled on timolol.Intraocular pressure over 24 hours after single-dose administration of latanoprost 0.005% in healthy volunteers. A randomized, double-masked, placebo controlled, cross-over single center study.Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma.Effect of latanoprost on cultured porcine corneal stromal cells.
P2860
Q22305849-CB8F725B-0D6C-45AB-B00C-D7BF68486EB1Q24672885-60242517-DF9E-410E-AA4A-D24B8C9AA0EBQ28360261-AF806603-FC5A-4920-92B4-3FC5369DF073Q30327343-7678CFFB-B546-432E-8AD8-991B9EEFB626Q33343120-E575FD89-3C95-40E8-AED8-5B88CE1531ADQ33521178-252449B4-F138-40DF-BEA6-DA4366FC2005Q33687798-793E7122-9611-4FF8-9DA2-0F897A3F5260Q33900179-6D0A73BF-DB00-4F1F-8FDA-7B3A80B3045CQ33996251-A786A81F-B2CB-4389-AB50-967BA80813BCQ34043309-D777234D-A7B0-4886-A320-AD298D526435Q34204357-247B92A4-0CC4-4123-A050-8745723C0977Q34204376-285E7F34-FC99-4990-ADD0-27F8937462B7Q34511054-2897B947-4F96-4A63-8634-CB725DEE06C1Q35298399-4EA67A49-AA2D-48BD-AD16-A42067D4F443Q35313371-A85825FD-50A9-43B6-9B41-DD2F6CF11B61Q35581180-F67935E8-4DC3-4C5E-8851-0D7503C68472Q35589367-6647EEB1-0C7D-4710-B72C-24E740461C97Q35753429-4EC7906B-0CD3-4F97-BF34-355884AE5577Q35775628-641E78D7-6FC5-4B52-964F-61348AF69270Q37288768-7E1B3942-7775-42A2-BC70-8CD35493309AQ37986149-66C6A5F5-B8D6-4FA8-B6AF-C6BD9EFFA840Q41279476-D02CDBF8-CB05-4039-AE51-0C0662853719Q42144823-BEF16C46-943F-4DD6-A82D-CD9CF50B0377Q43216533-2426C971-0334-4996-A309-A2E54CF65515Q43563756-7C5CE4C2-6D68-4C8E-9832-FCE815BCADAAQ43636701-4D15A357-9FFF-4206-BF15-656FAA090B09Q43848491-1D868C01-7642-427F-B6A5-5E6C2D45CD0AQ44787265-704E94B2-A0BC-4D88-8BD7-56C54D69F999Q46775923-1007A6BF-25AC-4888-ADBC-F55B3C079BAF
P2860
Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 1995
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Latanoprost administered once ...... ed concomitantly with timolol.
@en
Latanoprost administered once ...... ed concomitantly with timolol.
@nl
type
label
Latanoprost administered once ...... ed concomitantly with timolol.
@en
Latanoprost administered once ...... ed concomitantly with timolol.
@nl
prefLabel
Latanoprost administered once ...... ed concomitantly with timolol.
@en
Latanoprost administered once ...... ed concomitantly with timolol.
@nl
P2093
P2860
P356
P1476
Latanoprost administered once ...... ed concomitantly with timolol.
@en
P2093
Friström B
Kjellgren D
Stjerschantz J
Söderström M
Widengård I
P2860
P356
10.1136/BJO.79.1.12
P407
P577
1995-01-01T00:00:00Z